• 1
    Reynolds TB. Ascites. Clin Liver Dis 2000; 4: 15168.
  • 2
    Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 11517.
  • 3
    Salerno F, Gerbes A, Wong F, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 13108.
  • 4
    Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International ascites Club. Hepatology 1996; 23: 16476.
  • 5
    Gines P, Fernandez-Esparrach G, Arroyo V, et al. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997; 17: 17589.
  • 6
    Arroyo V, Badalamenti S, Gines P. Pathogenesis of ascites in cirrhosis. Minerva Med 1987; 78: 64550.
  • 7
    Schrier RW, Niederberger M, Weigert A, et al. Peripheral arterial vasodilatation: determinant of functional spectrum of cirrhosis. Semin Liver Dis 1994; 14: 1422.
  • 8
    Ruiz-del-Arbol L, Urman J, Fernandez J, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38: 12108.
  • 9
    Bernardi M, Trevisani F, Santini C, et al. Aldosterone related blood volume expansion in cirrhosis before and after the early phase of ascites formation. Gut 1983; 24: 7616.
  • 10
    DiBona GF, Sawin LL. Hepatorenal baroreflex in cirrhotic rats. Am J Physiol 1995; 269: 2933.
  • 11
    Jalan R, Forrest EH, Redhead DN, et al. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? Gut 1997; 40: 66470.
  • 12
    Ming Z, Smyth DD, Lautt WW. Decreases in portal flow trigger a hepatorenal reflex to inhibit renal sodium and water excretion in rats: role of adenosine. Hepatology 2002; 35: 16775.
  • 13
    Witte MH, Witte CL, Dumont AE. Progress in liver disease: physiological factors involved in the causation of cirrhotic ascites. Gastroenterology 1971; 61: 74250.
  • 14
    Witte CL, Witte MH, Dumont AE. Lymph imbalance in the genesis and perpetuation of the ascites syndrome in hepatic cirrhosis. Gastroenterology 1980; 78: 105968.
  • 15
    Shear L, Ching S, Gabuzda GJ. Compartmentalization of ascites and oedema in patients with hepatic cirrhosis. N Engl J Med 1970; 282: 13915.
  • 16
    Krag A, Bendtsen F, Henriksen JH, et al. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010; 59: 10510.
  • 17
    Wong F, Liu P, Lilly L, et al. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond.) 1999; 97: 25967.
  • 18
    Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38: 25866.
  • 19
    Planas R, Montoliu S, Ballestè B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006; 4: 138594.
  • 20
    Bernardi M, Laffi G, Salvagnini M, et al. Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content. Liver 1993; 13: 15662.
  • 21
    Gatta A, Angeli P, Caregaro L, et al. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology 1991; 14: 2316.
  • 22
    Ginès P, Cárdenas A, Arroyo V, et al. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 164654.
  • 23
    Salerno F, Borroni G, Moser P, et al. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients. Am J Gastroenterol 1993; 88: 5149.
  • 24
    D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 21731.
  • 25
    Bernardi M, Domenicali M. The renin–angiotensin–aldosterone system in cirrhosis. In: SchrierRW, ArroyoV, RodésJ, GinésP, eds. The Liver and the Kidney. Malden, MA: Blackwell Sci Pub, 2005; 4353.
  • 26
    Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 38: S6989.
  • 27
    Bernardi M, Rubboli A, Trevisani F, et al. Reduced cardiovascular responsiveness to exercise-induced sympatho-adrenergic stimulation in patients with cirrhosis. J Hepatol 1991; 12: 20716.
  • 28
    Bernardi M, Servadei D, Trevisani F, et al. Importance of plasma aldosterone concentration on natriuretic effect of spironolactone in patients with liver cirrhosis and ascites. Digestion 1985; 31: 18993.
  • 29
    Pokros TJ, Reynolds TB. Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. Gastroenterology 1986; 90: 182733.
  • 30
    Arroyo V, Ginés P, Rimola A, et al. Renal function abnormalities, prostaglandins, and effects of non-steroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis. Am J Med 1986; 81 (Suppl. 2B): 10422.
  • 31
    Salerno F, Badalamenti S. Drug-induced renal failure in cirrhosis. In: ArroyoP, GinèsJ, RodésRW, Schrier, eds. Ascites and Renal Dysfunction in Liver Disease, 2nd edn. Oxford, UK: Blackwell Science, 2005; 3728.
  • 32
    Fasolato S, Angeli P, Dallagnese L, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007; 45: 2239.
  • 33
    Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009; 49: 208710.
  • 34
    Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006; 55 (Suppl. 6): vi112.
  • 35
    Ginès P, Arroyo V, Vargas V, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 1991; 325: 82935.
  • 36
    Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 1956; ii: 11215.
  • 37
    Gordon ME. The acute effects of abdominal paracentesis in Laennec's cirrhosis upon exchanges of electrolytes and water, renal function, and haemodynamics. Am J Gastroenterol 1960; 33: 1537.
  • 38
    Gines P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987; 93: 23441.
  • 39
    Salerno F, Badalamenti S, Incerti P, et al. Repeated paracentesis and i.v. albumin infusion to treat tense ascites in cirrhotic patients. A safe alternative therapy. J Hepatol 1987; 5: 1028.
  • 40
    Gines P, Planas R, Angeli P, et al. Treatment of patients with cirrhosis and refractory ascites by LeVeen shunt with titanium tip. Comparison with therapeutic paracentesis. Hepatology 1995; 22: 12431.
  • 41
    Pache I, Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther 2005; 21: 5259.
  • 42
    DeGottardi A, Thevenot T, Spahr L, et al. Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Gastroenterol Hepatol 2009; 7: 9069.
  • 43
    Grabau CM, Crago SF, Hoff LK, et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004; 40: 4848.
  • 44
    McVay PA, Toy PTCY. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991; 31: 16471.
  • 45
    Thomsen TW, Shaffer RW, White B, et al. Videos in clinical medicine. Paracentesis. N Engl J Med 2006; 355: e21.
  • 46
    Ruiz-del-Arbol L, Monescillo A, Jiménez W, et al. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113: 57986.
  • 47
    Pozzi M, Osculati G, Boari G, et al. Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology 1994; 106: 70919.
  • 48
    Ginès P, Titó L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493502.
  • 49
    Panos MZ, Moore K, Vlavianos P, et al. Single, total paracentesis for tense ascites: sequential hemodynamic changes and right atrial size. Hepatology 1990; 11: 6627.
  • 50
    Ginès A, Fernández-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 100210.
  • 51
    Salerno F, Badalamenti S, Lorenzano E, et al. Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology 1991; 13: 70713.
  • 52
    Cardenas A, Gines P, Runyon BA. Is albumin infusion necessary after large volume paracentesis? Liv Int 2009; 29: 63640.
  • 53
    Fassio E, Terg R, Landeira G, et al. Paracentesis with dextran 70 vs paracentesis with albumin in cirrhosis with tense ascites. J Hepatol 1992; 14: 3106.
  • 54
    Cabrera J, Inglada L, Quintero E, et al. Large-volume paracentesis and intravenous saline: effects on the renin–angiotensin system. Hepatology 1991; 14: 10258.
  • 55
    Arroyo V, Sort P, Gines P, et al. Treatment of ascites by paracentesis. In: ArroyoV, GinesP, RodesJ, SchrierRW, eds. Ascites and Renal Dysfunction in Liver Disease. Melbourne: Blackwell Sci, 1999; 46379.
  • 56
    Moreau R, Valla DC, Durand-Zaleski I, et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomized controlled pilot trial. Liver Int 2006; 26: 4654.
  • 57
    Moreau R, Asselah T, Condat B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002; 50: 904.
  • 58
    Appenrodt B, Wolf A, Grunhage F, et al. Prevention of paracentesis induced circulatory dysfunction: midodrine versus albumin. A randomized pilot study. Liver Int 2008; 28: 101925.
  • 59
    Singh V, Deherendra PC, Singh B, et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol 2009; 103: 1399405.
  • 60
    Gordon JD, Colapinto RF, Abecassis M, et al. Transjugular intrahepatic portosystemic shunt: a nonoperative approach to life threatening variceal bleeding. Can J Surg 1987; 30: 459.
  • 61
    Nakamura K, Takashima S, Kichikawa K, et al. Portal decompression after transjugular intrahepatic portosystemic shunt creation with use of a spiral Z stent. J Vasc Interv Radiol 1993; 4: 8590.
  • 62
    Wong F, Snidermann K, Liu P, et al. Transjugular intrahepatic stent shunt effects on haemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med 1995; 122: 81622.
  • 63
    Lebrec D, Giuily N, Hadengue A, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: randomized trial. J Hepatol 1996; 25: 13544.
  • 64
    Rossle M, Ochs A, Gulberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 17017.
  • 65
    Gines P, Uriz J, Calahorra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 183947.
  • 66
    Sanyal AJ, Genning C, Reddy KR, et al. The north American study for the treatment of refractory ascites. Gastroenterology 2003; 124: 63441.
  • 67
    Salerno F, Merli M, Riggio O, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004; 40: 62935.
  • 68
    D'Amico G, Luca A, Morabito A, et al. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology 2005; 129: 128293.
  • 69
    Wong W, Liu P, Blendis LM, et al. Renal sodium handling during long term follow-up and the effect of sodium loading in cirrhotic patients treated with TIPS for refractory ascites. Am J Med 1999; 106: 31522.
  • 70
    Allard JP, Chau J, Sandokji K, et al. Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites. Am J Gastroenterol 2001; 96: 24427.
    Direct Link:
  • 71
    Salerno F, Cammà C, Enea M, et al. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133: 82534.
  • 72
    Sanyal AJ, Freedman AM, Luketic VA, et al. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997; 112: 88998.
  • 73
    Barrio J, Ripoll C, Banares R, et al. Comparison of transjugular intrahepatic portosystemic shunt dysfunction in PTFE-covered stent grafts versus bare stents. Eur J Radiol 2005; 55: 1204.
  • 74
    Angermayr B, Cejna M, Koenig F, et al. Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stent grafts versus bare stents. Hepatology 2003; 38: 104350.
  • 75
    Rossi P, Salvatori F, Fanelli F, et al. Polytetrafluorethylene covered nitinol stent-graft for transjugular intrahepatic portosystemic shunt creation: 3-year experience. Radiology 2004; 231: 8203.
  • 76
    Sanyal AJ, Freedman AM, Shiffman ML, et al. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology 1994; 20: 4655.
  • 77
    Jalan R, Elton RA, Redhead DN, et al. Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage. J Hepatol 1995; 23: 1238.
  • 78
    Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol 2005; 42: 6749.
  • 79
    Kerlan RK Jr, LaBerge JM, Baker EL, et al. Successful reversal of hepatic encephalopathy with intentional occlusion of transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol 1995; 6: 91721.
  • 80
    Sanyal AJ, Freedman AM, Purdum PP, et al. The hematologic consequences of transjugular intrahepatic portosystemic shunts. Hepatology 1996; 23: 329.
  • 81
    Salerno F, Merli M, Cazzaniga M, et al. MELD score is better than Child–Pugh score in predicting 3-month survival in patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol 2002; 36: 494500.
  • 82
    Mizrahi M, Adar T, Shouval D, et al. Endotipsitis-persistent infection of transjugular intrahepatic portosystemic shunt: pathogenesis, clinical features and management. Liv Int 2010; 30: 17583.
  • 83
    Silva RF, Arroyo PC Jr, Duca WJ, et al. Complications following transjugular intrahepatic portosystemic shunt: a retrospective analysis. Transplant Proc 2004; 36: 9268.
  • 84
    Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension: update 2009. Hepatology 2010; 51: 306.
  • 85
    Salerno F, DelBo A, Maggi A, et al. Vasopressin release and water metabolism in patients with cirrhosis. J Hepatol 1994; 21: 82230.
  • 86
    Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006; 69: 212430.
  • 87
    Decaux G, Soupart A, Vassart G. Non-peptide arginine–vasopressin antagonists: the vaptans. The Lancet 2008; 371: 162432.
  • 88
    Gines P, Wong F, Watson H, et al. Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium concentration in cirrhosis with hyponatremia. A randomized trial. Hepatology 2008; 48: 20413.
  • 89
    Gines P, Wong F, Watson H, et al. Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia – a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2010; 31: 83445.
  • 90
    Castellote J, Girbau A, Maisterra S, et al. Spontaneous bacterial peritonitis and bacterascites prevalence in symptomatic cirrhotic outpatients undergoing large-volume paracentesis. J Gastroenterol Hepatol 2008; 23: 2569.
  • 91
    Garcia-Tsao G. Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol 2005; 42 (Suppl.): S8592.
  • 92
    Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 4039.
  • 93
    Gines P, Navasa M. Antibiotic prophylaxis for spontaneous bacterial peritonitis: how and whom? J Hepatol 1998; 29: 4904.
  • 94
    Fernandez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 81824.
  • 95
    Gerbes AL, Gulberg V. Benefit of TIPS for patients with refractory or recidivant ascites: serum bilirubin may make the difference. Hepatology 2005; 41: 217.
  • 96
    Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunt. Hepatology 2000; 31: 86471.